KR900017573A - 피페리디노알칸올-이부프로펜 조합용 제약 조성물 - Google Patents

피페리디노알칸올-이부프로펜 조합용 제약 조성물 Download PDF

Info

Publication number
KR900017573A
KR900017573A KR1019890007550A KR890007550A KR900017573A KR 900017573 A KR900017573 A KR 900017573A KR 1019890007550 A KR1019890007550 A KR 1019890007550A KR 890007550 A KR890007550 A KR 890007550A KR 900017573 A KR900017573 A KR 900017573A
Authority
KR
South Korea
Prior art keywords
layer
composition
amount
pharmaceutically acceptable
present
Prior art date
Application number
KR1019890007550A
Other languages
English (en)
Other versions
KR0126129B1 (ko
Inventor
쇼크 허버트
프란시스 롱 데이비드
리챠드 나들러 윌리암
Original Assignee
게리 디. 스트리트
머렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 머렐 다우 파마슈티칼스 인크. filed Critical 게리 디. 스트리트
Publication of KR900017573A publication Critical patent/KR900017573A/ko
Application granted granted Critical
Publication of KR0126129B1 publication Critical patent/KR0126129B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

피페리디노알칸올-이부프로펜 조합용 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. a)제약상 허용되는 부형제와 혼합된, 진통 및 해열치료 유효량의 이부프로펜 또는 제약상 허용되는 그의 염을 함유하는 층, b) 제약상 허용되는 부형제와 혼합된 항히스타민 치료 유효량의 피페리디노알칸올 또는 제약상 허용되는 그의 염을 함유하는 층, c)상기 이부프로펜 함유층 및 상기 피레리디노 알칸올 함유층의 두층 사이에 차단막을 제공하기 위한 상기 두 층 사이의 산재된 제약상 허용되는 부형제를 함유하는 층으로 이루어진 고상 단위 투여 형태의 다층 제약 정제.
  2. 제1항에 있어서, 상기 차단막이 정제의 전체 중량에 기초하여 약 5 내지 40중량%의 양으로 존재하는 조성물.
  3. 제1항에 있어서, 상기 차단층이 정제의 전체 중량에 기초하여 약 5 내지 30중량%의 양으로 존재하는 조성물.
  4. 제1항에 있어서, 상기 차단층이 정제의 전체 중량에 기초하여 약 10 내지 15중량%의 양으로 존재하는 조성물.
  5. 제4항에 있어서, 상기 차단층이 희석제와 결합제로 구성된 조성물.
  6. 제5항에 있어서, 상기 차단층이 희석제와 미세 결정성 셀룰로오스인 조성물.
  7. 제1항에 있어서, 적어도 한 층이 교감신경 흥분성 충혈제거제를 함유하는 조성물.
  8. 제5항에 있어서, 상기 피페리디노알칸을 항히스타민제층이 추가로 교감신경흥분성 충혈제거제를 함유하는 조성물.
  9. 제8항에 있어서, 상기 교감신경흥분성 충혈제거제가 슈도에페드린(pseudoephedrine) 이고, 상기 피페리딘 알칸올이 α-〔4-(1,1-디메틸에틸)페닐〕-4-(히드록시디페닐메틸)-1-피페린딘부탄올이며, 상기 이부프로펜이 2-(p-이소부틸페닐) 프로피온산이거나 이들 화합물의 제약상 허용되는 염인 이 화합물의 조성물.
  10. 제9항에 있어서, a)상기 이부프로펜이 약 100mg 내지 약 300mg의 양으로 존재하고, b)상기 슈도에페드린이 약 15mg 내지 약60mg의 양으로 존재하며, c)상기 α-〔4-(1,1-디메틸에틸)페닐〕-4-(히드록시디페닐메틸)-1-피페리딘부탄올이 약 15 내지 약 60mg의 양으로 존재하는 조성물.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019890007550A 1988-06-01 1989-05-31 피페리디노알칸올-이부프로펜 조합용 제약 조성물 KR0126129B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20081788A 1988-06-01 1988-06-01
US200,817 1988-06-01
US7/200,817 1988-06-01
US07/344,183 US4999226A (en) 1988-06-01 1989-04-27 Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US344.183 1989-04-27
US344,183 1989-04-27

Publications (2)

Publication Number Publication Date
KR900017573A true KR900017573A (ko) 1990-12-19
KR0126129B1 KR0126129B1 (ko) 1997-12-24

Family

ID=26896133

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007550A KR0126129B1 (ko) 1988-06-01 1989-05-31 피페리디노알칸올-이부프로펜 조합용 제약 조성물

Country Status (17)

Country Link
US (1) US4999226A (ko)
EP (1) EP0348683B1 (ko)
JP (1) JP2757017B2 (ko)
KR (1) KR0126129B1 (ko)
CN (1) CN1038021A (ko)
AU (1) AU615751B2 (ko)
CA (1) CA1327011C (ko)
DE (1) DE68900378D1 (ko)
DK (1) DK174638B1 (ko)
ES (1) ES2037908T3 (ko)
FI (1) FI90205C (ko)
GR (1) GR3003477T3 (ko)
HU (1) HU202746B (ko)
IE (1) IE61182B1 (ko)
IL (1) IL90461A0 (ko)
NZ (1) NZ229325A (ko)
PT (1) PT90689B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
JPH069382A (ja) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd 安定化された固型製剤およびその製造方法
EP0674527A1 (en) * 1992-12-21 1995-10-04 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
SK279684B6 (sk) * 1993-06-14 1999-02-11 Janssen Pharmaceutica N.V. Tableta a spôsob jej výroby
CA2173467A1 (en) * 1993-10-25 1995-05-04 Keith D. Ertel A stable pharmaceutical composition of terfenadine and ibuprofen
PT812589E (pt) * 1993-12-10 2000-11-30 Fujisawa Pharmaceutical Co "farmaco combinado antipiretico e analgesico"
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5399356A (en) * 1994-03-24 1995-03-21 The Procter & Gamble Company Process for making solid dose forms containing bismuth
EP0812195B1 (en) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
EP2305219A1 (en) * 2000-11-17 2011-04-06 Takeda Pharmaceutical Company Limited Pharmaceutical preparations coated with a copolyvidone-containing coating
BR0212950A (pt) * 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas tendo uma porção inserida
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
CN1997331A (zh) * 2004-05-21 2007-07-11 阿库-伯雷克技术公司 在药片一面上含有分离标记的药片
AU2005245028B2 (en) * 2004-05-21 2010-12-09 Accu-Break Technologies, Inc. Pharmaceutical tablets having a relatively inactive segment
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2007073702A2 (es) 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
WO2010078541A1 (en) * 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
CA2748728C (en) 2009-01-05 2017-01-03 Mcneil-Ppc, Inc. Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer
WO2010078542A1 (en) * 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
US20130115250A1 (en) * 2009-05-13 2013-05-09 Wyeth Llc Burst Drug Release Compositions
RU2764849C2 (ru) 2016-12-09 2022-01-21 Байер Энимэл Хельс ГмбХ Фармацевтический препарат и способ его получения
CN108703828B (zh) * 2018-06-04 2021-03-30 王荣涛 下肢牵引器
CN109481272B (zh) * 2019-01-10 2020-07-24 河南省洛阳正骨医院（河南省骨科医院） 肺癌骨转移术后康复装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4882167A (en) * 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method

Also Published As

Publication number Publication date
DK265489A (da) 1989-12-02
IE891795L (en) 1989-12-01
CA1327011C (en) 1994-02-15
PT90689B (pt) 1993-12-31
FI90205B (fi) 1993-09-30
US4999226A (en) 1991-03-12
DK174638B1 (da) 2003-08-04
FI892640A (fi) 1989-12-02
PT90689A (pt) 1989-12-29
JP2757017B2 (ja) 1998-05-25
FI90205C (fi) 1994-01-10
EP0348683A1 (en) 1990-01-03
ES2037908T3 (es) 1993-07-01
AU615751B2 (en) 1991-10-10
AU3580089A (en) 1989-12-07
DK265489D0 (da) 1989-05-31
CN1038021A (zh) 1989-12-20
HU202746B (en) 1991-04-29
KR0126129B1 (ko) 1997-12-24
EP0348683B1 (en) 1991-10-30
IL90461A0 (en) 1990-01-18
JPH0228111A (ja) 1990-01-30
FI892640A0 (fi) 1989-05-31
IE61182B1 (en) 1994-10-05
DE68900378D1 (de) 1991-12-05
GR3003477T3 (en) 1993-02-17
NZ229325A (en) 1990-10-26
HUT52367A (en) 1990-07-28

Similar Documents

Publication Publication Date Title
KR900017573A (ko) 피페리디노알칸올-이부프로펜 조합용 제약 조성물
US4975426A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
Holmér Pettersson et al. Early bioavailability of paracetamol after oral or intravenous administration
US4839354A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US5204118A (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
EP0316434B1 (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
KR930007450A (ko) 트라마돌 및 비-스테로이드성 소염제를 함유하는 조성물
Amadio Jr et al. Nonsteroidal anti-inflammatory drugs: Tailoring therapy to achieve results and avoid toxicity
RU2005122403A (ru) Композиции нестероидных противовоспалительных лекарственных средств, противозастойных средств и антигистаминов
AU2080388A (en) A pharmaceutical composition containing s(+) ibuprofen substantially free of its r(-) antipode
KR830005854A (ko) 알카리성 진통제 캡슐의 제조방법
JP2005509597A5 (ko)
GB2287404A (en) Antiinflammatory and analgesic compositions
EP0465235A1 (en) Pharmaceutical compositions and methods for alleviating gastrointestinal symptoms induced by nonsteroidal anti-inflammatory drugs
US6900189B2 (en) Analgesic and glucosamine compositions
KR920002149A (ko) 비스테로이드계 소염제에 의해 유발된 위장 장애 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법
KR920016094A (ko) 전혈청 콜레스테롤, ldl 콜레스테롤 및 트리글리세라이드를 저하시키기 위한 테니다프를 함유하는 제약 조성물
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
Hagley et al. Suspected cross-reactivity of enalapril-and captopril-induced hepatotoxicity
Dixon et al. Interactions between non-steroidal anti-inflammatory drugs and H 2-receptor antagonists or prostaglandin analogues
Vischer Efficacy and tolerability of tenoxicam–An overview
DE3581006D1 (de) Feste orale arzneiformen mit gestaffelter wirkung zur verabreichung von wirkstoffen mit geschwuere erzeugender nebenwirkung.
Morise et al. Molecular mechanisms involved in NSAID-induced gastropathy
WO2002069968A8 (en) New use
KR910014337A (ko) d-2-(6-메톡시-2-나프릴)-프로피온산의 광학활성 유도체와 이것을 함유한 약제학적 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110921

Year of fee payment: 15

EXPY Expiration of term